The Indian pharmaceutical market (IPM) expanded by 7.9% in July 2025, according to a recent Pharmarack report.
Cardiac and anti-diabetes therapy segments recorded significant value growth of 14.1% and 9%, respectively, making up nearly a quarter of the overall domestic market.
Other segments, such as urology, antineoplastics, and respiratory therapies, also showed double-digit value increases.
Pharmarack’s Vice President (Commercial), Sheetal Sapale, noted, “New introductions and price growth have driven the market growth for the month of July for most of the therapies.”
“Among the top therapies, only cardiac and anti-infectives have a strong volume growth. New introductions also drove the growth in the anti-diabetes segment,” Sapale further added.
GLP-1 Agonists Market
Semaglutide and Tirzepatide, key drugs for type 2 diabetes and weight loss, continue to fuel growth in the GLP-1 agonists market.
Semaglutide is marketed as Rybelsus (oral) and Wegovy (injections), while Tirzepatide is sold under the brand Mounjaro. Aggressive promotion helped sustain strong sales momentum for these treatments.
The report also highlights the increasing importance of biologics and biosimilars in the Indian pharma landscape.
The biosimilars market, currently valued at around ₹3,900 crore, is growing at a five-year compound annual growth rate (CAGR) of 15%. These therapies are becoming crucial as disease patterns evolve and treatment complexities increase.
The sustained growth across diverse therapy areas underscores the dynamic nature of India’s pharmaceutical sector.
Ongoing innovation and a strategic focus on biologics and biosimilars are driving the market’s continued expansion, significantly contributing to healthcare outcomes nationwide.
Also Read: India’s Electronics Exports Surge 47% In Q1 FY26, Led By Mobile Phones
To read more such news, download Bharat Express news apps
